These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10933647)

  • 1. Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with pefloxacin.
    Tullio V; Cuffini AM; Bonino A; Palarchio AI; Roana J; Mandras N; Rossi V; Carlone NA
    J Antimicrob Chemother; 2000 Aug; 46(2):241-7. PubMed ID: 10933647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pefloxacin and immunity: cellular uptake, potentiation of macrophage phagocytosis and intracellular bioactivity for Klebsiella pneumoniae.
    Cuffini AM; Tullio V; Fazari S; Allocco A; Carlone NA
    Int J Tissue React; 1992; 14(3):131-9. PubMed ID: 1446977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF 3013 against Klebsiella pneumoniae.
    Tullio V; Cuffini AM; Bonino A; Ianni Palarchio A; Rossi V; Carlone NA
    Drugs Exp Clin Res; 1999; 25(1):1-11. PubMed ID: 10337499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones.
    Prats G; Roig C; Miró E; Navarro F; Mirelis B
    Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):328-34. PubMed ID: 12072950
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of rufloxacin upon non-specific immune defences: in-vitro, ex-vivo and in-vivo results.
    Cuffini AM; Tullio V; Allocco A; Paizis G; De Leo C; Carlone NA
    J Antimicrob Chemother; 1994 Oct; 34(4):545-53. PubMed ID: 7868406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
    Montanari MP; Mingoia M; Varaldo PE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic characteristics of prulifloxacin.
    Matera MG
    Pulm Pharmacol Ther; 2006; 19 Suppl 1():20-9. PubMed ID: 16360331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
    Araake M; Hara T; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prulifloxacin.
    Keam SJ; Perry CM
    Drugs; 2004; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of ofloxacin, pefloxacin, and tobramycin on the hydrophobicity of Klebsiella pneumoniae].
    Hostacká A
    Epidemiol Mikrobiol Imunol; 1999 Feb; 48(1):28-30. PubMed ID: 11038674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains.
    Martínez-Martínez L; García I; Ballesta S; Benedí VJ; Hernández-Allés S; Pascual A
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1850-2. PubMed ID: 9661034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Klebsiella pneumoniae and Enterobacter cloacae with fluoroquinolone resistance-associated amino acid alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Kawamura T; Takahashi Y; Okezaki E; Nagata O; Kato H; Kawada Y
    J Antimicrob Chemother; 1997 Dec; 40(6):907-9. PubMed ID: 9462448
    [No Abstract]   [Full Text] [Related]  

  • 14. [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens].
    Smirnova LB; Sokolova VI
    Antibiot Khimioter; 2000; 45(7):14-6. PubMed ID: 10987102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prulifloxacin: a new antibacterial fluoroquinolone.
    Prats G; Rossi V; Salvatori E; Mirelis B
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
    Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I
    Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
    Mikamo H; Kawazoe K; Izumi K; Ito K; Tamaya T
    Drugs; 1995; 49 Suppl 2():326-30. PubMed ID: 8549350
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
    Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.